Pharmacological properties of the Thyrokitty injection (I-131) for the treatment of the feline hyperthyroidism

서지정보

ㆍ발행기관 : 충북대학교 동물의학연구소 ㆍ수록지정보 : Journal of Biomedical and Translational Research / 23권 / 4호
ㆍ저자명 : Jae Cheong Lim, Da Mi Kim, Sung Soo Nam, Eun Ha Cho, So-Young Lee, Hye Kyung Chung, Inki Lee

목차

Abstract
INTRODUCTION
MATERIALS AND METHODS
시험물질의 품질 확인 시험
세포 배양
세포 섭취율 시험
세포 사멸 효과 시험
실험동물 사육 관리
조직 분포 및 배설 시험을 위한 시험물질의 제조 및 투여
생체 내 조직 분포 시험
생체 내 배설 시험
통계 분석
RESULTS
시험물질의 품질 확인
세포 섭취율 평가
세포 사멸 효과 평가
조직 분포 및 배설 시험을 위한 시험물질의 제조 및 투여
생체 내 조직 분포 시험; 각 시간대별 조직 내 분포(%ID/organ)
생체 내 조직 분포 시험; 각 시간대별 조직 내 분포(%ID/g)
생체 내 조직 분포 시험; 조직 내 분포(%ID/g)의 약동학적 파라미터(PK parameter) 산출
생체 내 배설 시험
DISCUSSION
SUPPLEMENTARY MATERIALS
REFERENCES

영어 초록

Radioiodine (131I) has been used for the treatment of feline hyperthyroidism since the 1990s in the USA and Europe, and it is recommended as the most effective treatment for feline hyperthyroidism because it has a high therapeutic effect, small side effects, and does not require anesthesia. In this study, the pharmacological properties of the Thyrokitty injection (I-131), which is being developed as a treatment for feline hyperthyroidism, using radioiodine (131I) as an active ingredient, was tested. The %cell uptake of the Thyrokitty injection (I-131) in FRTL- 5 thyroid cells was 0.410 ± 0.016%, which was about 18 times higher compared to Clone 9 hepatocytes, and it was decreased by 30.7% due to the competitive reaction with iodine (sodium iodide). In addition, the %cell growth of the FRTL-5 thyroid cells was reduced by 25.0% by treatment with the Thyrokitty injection (I-131). As a result of the tissue distribution test, the Thyrokitty injection (I-131) was distributed at the highest concentration at 0.083 hours (5 minutes) after subcutaneous administration to animals in most organs except the stomach, small intestine, large intestine, muscle and thyroid gland, and it was excreted mainly through the kidneys. The stomach and thyroid gland showed a typical distribution pattern observed when radioiodine (131I) was administered. In addition, about 78.45% of the total amount of excretion was excreted within 48 hours, of which more than 85% was excreted in urine. In conclusion, the Thyrokitty injection (I-131) has the same mechanism of action, potency, absorption, distribution, metabolism and excretion characteristics as radioiodine (131I) reported in connection with the treatment of feline hyperthyroidism. In the future, using the results of this study, it is expected that the Thyrokitty (I-131) could be safely used in the clinical treatment of feline hyperthyroidism.

참고 자료

없음